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The field of cancer therapeutics is moving towards the development of targeted 
cancer therapies – therapies that selectively kill cancer cells by targeting genomic 
features crucial to tumor survival. Compound 1B is a novel cytotoxic agent that is 
selectively toxic to 4% of cancer cell lines.  After sensitive cell lines were treated with 
the compound for 48 hours, they exhibited apoptotic cell death with a half maximal 
effective concentration (EC50) in the low nanomolar range.  This study represents the 
initial steps in understanding the mechanism of selective toxicity of Compound 1B using 
a two pronged approach that includes predicting the binding of Compound 1B to its 
proposed target phosphodiesterase 3A (PDE3A) using available structural information, as 
well as investigating experimentally its effect on the enzymatic activity PDE3A.  Our 
findings suggest that Compound 1B binds to the catalytic domain of PDE3A, and 
therefore acts as a competitive inhibitor of cAMP hydrolysis.  In order to validate that 
PDE3A was interacting with Compound 1B and to measure the effect of the compound 
on the kinetics of PDE3A, an enzymatic activity assay was developed.  Our results 
showed that Compound 1B bound to the catalytic site of PDE3A, inhibiting its cAMP 
hydrolysis function in a similar manner to known competitive PDE3A inhibitors.  
Additionally, Compound 1B affected the kinetics of PDE3A in a similar manner to 
competitive inhibitors Zardaverine (lethal to Compound 1B-sensitive cell lines) and 
Cilostazol (non-lethal to Compound 1B-sensitive cell lines).  The interactions between 
Compound 1B and PDE3A were not unique to lethal compounds because Compound 1B 
interacted with PDE3A just as non-lethal Cilostazol did.  Therefore, the ability of 
Compound 1B to inhibit cAMP hydrolysis was not sufficient to explain the selective 
apoptosis observed in sensitive cell lines.  In the Hela cell line, Compound 1B competed 
with non-lethal PDE3A competitive inhibitors, as treatment with these inhibitors rescued 
the lethal effect of Compound 1B.  This result confirmed that the binding of Compound 
1B to PDE3A, as seen in vitro, occurred in cells and was linked to the cytotoxic 
phenotype of Compound 1B.  Compound 1B behaved as a competitive inhibitor of 
PDE3A in crystallized models, in vitro experimentation, and in the Hela cell line.  
Elucidating the functional effect of this competitive binding in terms of the connection to 
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Cancer is responsible for 7.6 million deaths worldwide and is projected to cause 
585,720 deaths in 2014 in the United States alone1.  Current treatment for cancer focuses 
on chemotherapeutic agents that kill rapidly dividing cells, a characteristic of cancer 
cells, but also a characteristic of cells that rapidly divide under normal circumstances 
such as cells of the bone marrow, digestive tract lining and hair follicles2.  The 
effectiveness of chemotherapy is substantially reduced by the side effects in normal 
tissues, such as kidney toxicity associated with cisplatin treatment, a common anti-cancer 
drug3.  Because of this toxicity, the therapeutic window of chemotherapy is narrow, and 
the dose for eradicating all of the cancer cells cannot usually be administered3.  Since all 
cancer cells are not typically killed during chemotherapy, small numbers of resistant 
populations of the cancerous cells can survive and will not be easily killed by subsequent 
treatments of traditional chemotherapy.   
Due to these drawbacks of traditional chemotherapy, modern cancer therapy 
presents a more focused approach for eradicating the cancer cells.  It centers on targeting 
cancer-specific genomic features deregulated in only cancer cells and not healthy cells.  
The first targeted cancer therapy was designed to inhibit estrogen from binding to 
estrogen receptors.  Because blocking estrogen from binding to the estrogen receptor had 
been shown to prevent breast cancer cell growth and proliferation, the FDA approved 
several drugs such as tamoxifen and toremifene4, which serve to specifically prevent 
estrogen from binding to the estrogen receptor.  
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Often, as in the case of the discovery of tamoxifen, the desired molecular target is 
identified, and molecules are developed to specifically interact with the target.  The small 
molecule investigated in this study, Compound 1B, is selectively toxic to few cancer cell 
lines, but its cellular target is unknown.  This study represents the initial steps in 
understanding the mechanism of selective toxicity of Compound 1B, a step crucial for the 
therapeutic application of the compound. 
 
Dose-Dependent Cytotoxic Effect of Compound 1B on Cancer Cell Lines  
Compound 1B originated from a small-molecule screen intended to find a mutant 
TP53 synthetic lethal compound, a compound that acts in combination with a mutation 
inherent in cancer cells to cause lethality (Heidi Greulich and Luc de Waal, Unpublished 
Data, 2012).  TP53 is the most frequently mutated gene across all cancers at rates of 95% 
in ovarian cancer, 84% in lung squamous cell carcinoma, and 51% in lung 
adenocarcninoma5.  Because TP53 regulates the cell cycle and conserves stability in the 
genome, mutations will often lead to unregulated cell division6.  Compound 1B was 
selected from the NIH’s Molecular Libraries Probe Production Center (MLPCN) pilot 
screen of 2,000 compounds because it was selectively toxic to a TP53 mutant cell line 
(H1734), but was not toxic to a TP53 wildtype cell line (A549), two non-isogenic cell 
lines that shared other major cancer drivers, KRAS and STK11.  
In order to gain an understanding of the genomic features that accounted for this 
sensitivity, the panel of cell lines treated with Compound 1B was extended.  Compound 
1B was found to be selectively toxic to 4% of the 766 cell lines in the Cancer Cell Line 
Encyclopedia (CCLE)7.  Representative cell lines, Hela (cervical cancer), A549, H1563 
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and H2122 (lung cancer epithelial cell lines) and MCF7 and PC3 (breast cancer cell lines) 
were incubated for 48 hours with Compound 1B (Figure 1).  Hela, H2122 and H1563 
cells showed a dose-dependent decrease in viability as concentration of Compound 1B 
increased from 0.1 pM to 300 µM.  The A549, MCF7, and PC3 cell lines however did not 
show a decrease in viability after treatment with Compound 1B until extremely high 
doses of compound at greater than 100 µM were administered.  Notably, there is a large 
variation among the sensitivity of the cell lines as seen by the 10,000 fold change in EC50 
values, a measure of the concentration of Compound 1B required to cause death in 50% 




Figure 1: Dose-Dependent Cytotoxic Effect of Compound 1B on the Viability of 
Cancer Cell Lines.  Cancer cell lines, Hela, A549, MCF7, PC3, H1563, and H2122, 
were treated with doses of Compound 1B from 0.1 pM to 300 µM for 48 hours.  Cell 
viability was assessed using the Cell-Titer Glo assay (Promega).  (Luc de Waal, 
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PDE3A, the Single Gene Correlate for Sensitivity to Compound 1B  
The cell line sensitivity data was used to predict a single gene that correlates with 
sensitivity to Compound 1B.  The Pearson product-moment correlation was used to 
measure the strength of the linear association between the two variables, sensitivity to 
Compound 1B and gene expression level.  Sensitivity was measured as area under the 
dose-response curve (AUC) from the upper plateau at 100% viability to 0% viability; 
regardless of whether a cell line reached this 0% viability, the total area to this point was 
still calculated.  As seen by the curves in Figure 1, a sensitive cell line would have a low 
AUC, and a nonsensitive cell line would have a high AUC.  PDE3A was the single 
significant gene correlate based on this input of the sensitive and the non-sensitive cell 
line mRNA expression levels (Figure 2).  PDE3A expression correlated with a low AUC 
and high sensitivity.  Figure 2B shows the distribution of cell lines in terms of their 
lineage, sensitivity to Compound 1B, and PDE3A expression.  Although skin cancer cell 
lines are overrepresented in the sensitive cell lines with high PDE3A mRNA expression, 
there is no correlation between all three variables.  Because high PDE3A expression was 
hypothesized to correlate with cell line sensitivity to Compound 1B, we sought to 
determine if PDE3A is a target of Compound 1B and if this interaction is responsible for 
the selective toxicity of the cell lines. 
	   9	  
 
Figure 2: PDE3A Predicted as Single Gene Correlate that Distinguished Compound 
1B Sensitive Cell Lines from Nonsensitive Cell Lines.  A. Pearson product-moment 
correlation found the strongest linear relationship between mRNA expression of PDE3A 
and cell line sensitivity to Compound 1B.  B. Sensitivity to Compound 1B from 
expression and sensitivity data of the 766 cell lines from the CCLE plotted as AUC (area 
under the curve of the viability assay from 100% viability to 0% viability) versus mRNA 
expression level of PDE3A transcript (Matt Reese, Unpublished Data, 2013). 
 
An Overview of PDE3A Biology 
PDE3 is one of 11 families of phosphodiesterases which all hydrolyze cyclic 
nucleotides but differ in their structure, substrate affinity, and regulation8.  The catalytic 
site for this hydrolysis is composed of about 270 amino acids at the C-terminal end of the 
protein and is highly conserved among the 11 families of phosphodiesterases (24-51% 
conservation)8.  The domain is primarily composed of alpha helices and is characterized 
by two divalent atoms, usually Mg2+ or Zn2+, crucial for its catalytic function8.  Within 
the PDE3 family there are two genes, PDE3A and PDE3B, which are structurally unique 
from the other phosphodiesterase families because they possess a 44 amino-acid insert in 
the catalytic domain, which physically acts as a flexible flap9.  PDE3A has three isoforms 
  
High expression of 
PDE3A and sensitive 
to Compound 1B 
A	   B	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(PDE3A1, PDE3A2, and PDE3A3), which are generated by alternative start sites in their 
translation10.  PDE3A1, the longest isoform, has the NHR1 domain, consisting of six 
hydrophobic regions at the N-terminus, presumed to be transmembrane domains since 
PDE3A1 is often localized to the membrane of the endoplasmic reticulum.  This domain 
has three phosphorylation sites which are phosphorylated by Protein Kinase A, B and C.  
PDE3A1 and PDE3A2 have the NHR2 domain, which has been shown to be important 
for its interaction with other proteins.   PDE3A3 is cytosolic, as it lacks the NHR1 
domain, the NHR2 domain, and the three phosphorylation sites11.  All three isoforms 
have been reported to have identical kinetic activity and respond in the same way to 
inhibitors12.  
Functionally, PDE3A has a high affinity for both cyclic adenosine 
monophosphate (cAMP) (Km = 80 nmol/L) and cyclic guanosine monophosphate 
(cGMP) (Km = 20 nmol/L)13.  PDE3A is termed a cyclic guanosine monophosphate 
(cGMP) inhibited cyclic nucleotide phosphodiesterase because cGMP binds to the same 
pocket as cAMP, but is hydrolyzed at a much slower rate and effectively inhibits the 
hydrolysis of cAMP13.  cAMP is a ubiquitous signaling molecule involved in major 
cellular proliferation, differentiation, and apoptotic pathways. The level of cyclic 
nucleotide monophosphate (cNMP) in the cell is controlled by a balance of its rate of 
production by adenylate or guanylate cyclases and rate of degradation by PDEs14.  
The PDE-regulated level of intracellular cAMP directly affects proteins such as 
ion channels, PKA, and exchange protein directly activated by cAMP (EPAC) (Figure 3).  
High levels of cAMP, for example, activate PKA by binding to its inhibitory subunits, 
rendering the catalytic subunits active15.  This activated kinase transfers a phosphate 
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group from ATP to serine or threonine side chains of its substrates, which include 
transcription factors, such as cAMP response element-binding protein (CREB) involved 
in proliferative, metabolic, and stress-response pathways16.  Overall, the target proteins 
regulated by the level of intracellular cAMP mediate cellular activities such as 
proliferation, apoptosis, differentiation and vasodilation16. 
 
Figure 3: An Overview of Phosphodiesterase Biology.  Phosphodiesterases hydrolyze 
cellular pools of cyclic nucleotides (cNMP) to product 5’-NMP.  The cNMP pool directly 
regulates the activity of proteins involved in cellular responses such as proliferation, 
apoptosis, differentiation, and vasodilation. Figure adapted from Savai et al., 201016.        
 
PDE3A plays a critical role in regulating the strength and duration of cAMP 
signaling.  Mechanistically, PDE3A hydrolyzes the phosphodiester bond of cyclic AMP 
or cyclic GMP, releasing 5’-AMP or 5’-GMP as product.   In the conserved active site, a 
water molecule is partially ionized to a hydroxide and forms a bridge between the two 
metal cations17.  This nucleophilic hydroxyl group attacks the phosphate in the cyclic 
phosphate ring of cAMP and breaks the ring.  A hydrogen bond network through a 
conserved glutamate and histidine allows for the stabilization of the oxygen that the 
phosphorus was once bound to17.  Figure 4 represents the reaction mechanism of cGMP 
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hydrolyzed by PDE9.  Because the histidine, glutamic acid, water molecule, and metal 
cations are conserved in across PDE families, the mechanism can be directly applied to 
PDE3.   
 
 
Figure 4: Reaction Mechanism of cGMP Hydrolysis of PDE917. Histidine, glutamic 
acid, and metal cations are residues highly conserved in the catalytic domain of all 
phosphodiesterases.  The schematic depicted the progression from enzyme+substrate 
(E+S), to enzyme/substrate (ES), to enzyme/product (EP), to enzyme+product (E+P).  
Potential hydrogen bonds were represented as dashed lines.  The substrate depicted is 
cGMP, but the same mechanism applies for cAMP.  Figure from Liu et al., 200817. 
 
Targeting PDE3A in Disease  
PDE3 inhibitors, such as Cilostazol,18,19 are used in clinical practice to treat heart 
failure resulting from a reduction in myocardial contractility.  Although extensively 
investigated, the mechanisms by which these inhibitors improve patient health are not 
well understood10.  It is thought that because these compounds inhibit the cAMP 
hydrolysis function of PDE3, the concentration of cAMP increases in myocytes.  An 
increased level of cAMP increases the phosphorylation of PKA substrates, such as 
calcium channels in muscle cells.  Calcium influx is important for systole, and therefore 
improves contraction of the heart.  Another PDE3 inhibitor, Zardaverine20,21 acts as a 
positive inotropic agent on heart muscle in vitro.  PDE3 inhibition also increases cAMP 
concentration in vascular smooth muscle, which relaxes the muscle and increases 
vasodilation.  PDE3 is expressed in platelets as well, and the same inhibitors cause an 
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increase in cAMP concentration, which leads to decreased platelet aggregation, therefore 
improving cardiac health10.   
Deregulation of proliferative cAMP-PDE3A pathways has been implicated in 
several cancers, as inhibited PDEs can also lead to inhibition of growth and apoptosis16,22. 
Yet unraveling the altered pathways is complex because PDE3A not only has several 
binding partners but also has unique regulation of each isoform.  PDE3A has been shown 
to form complexes with proteins such as 14-3-3 proteins, plectin, brefeldin A-inhibited 
guanine nucleotide exchange proteins, and CFTR (cystic fibrosis transmembrane 
conductance regulator channel), but potential binding partners of PDE3A in cancer cell 
lines are not well understood8,23,24. 
 
A Structural, Mechanistic and Functional Understanding of the Interaction of 
Compound 1B and PDE3A 
 
In this study, we attempted to elucidate the structural, mechanistic and functional 
effect of Compound 1B on its hypothesized target, PDE3A.  We manually docked 
Compound 1B to a model of PDE3 in order to predict the intermolecular interactions 
between Compound 1B and important residues in the binding pocket on PDE3A.  
Because the crystal structure of PDE3A is not available, we used the crystal structure of 
PDE3B for this structural analysis due to high conservation in the catalytic domain 
(Figure 5).  PDE3B was included in the mRNA expression Pearson correlation, but its 
expression did not correlate with cell sensitivity to Compound 1B.  However, in a Caliper 
phosphodiesterase enzyme activity assay, both PDE3A and PDE3B were inhibited by 
Compound 1B at about 97% (Luc de Waal, Unpublished Data, 2013).  Because 
Compound 1B could equally bind to PDE3B as PDE3A, we were confident that by 
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analyzing Compound 1B in the active site of PDE3B, we could accurately predict its 
binding interactions with PDE3A.  The predicted binding site and intermolecular 
interactions between Compound 1B and PDE3B were informed by models of interactions 
between PDE residues and compounds Zardavarine and Cilostazol. 
In order to understand the effect of Compound 1B on the cAMP hydrolysis 
function of PDE3A, an in vitro enzymatic activity assay was developed.  Using this 
assay, the ability of Compound 1B to inhibit the activity of purified PDE3A was 
compared to known inhibitors and structural analogs of Compound 1B.  Furthermore, the 
PDE3A activity assay was optimized for kinetic studies.  Comparison of the kinetic 
trends of Compound 1B to those of known competitive inhibitors, Zardavarine and 
Cilostazol, allowed us to gain insight on the mechanism by which Compound 1B inhibits 
PDE3A.  
Additionally, we connected our structural and mechanistic insight to the 
interaction between PDE3A and Compound 1B in the context of the sensitive Hela 
cancer cell line.  We determined if a correlation existed between the in vitro potencies 
and the lethality of the compounds to the Hela cell line.  This comparison was used to 
evaluate whether Compound 1B was selectively toxic to cancer cell lines because of its 
ability to inhibit the cAMP hydrolysis function of PDE3A or not.  By studying the 
interaction between Compound 1B and PDE3A, we aimed to gain a better understanding 
of what this interaction implies about the cytotoxic effect of Compound 1B to a subset of 
cancer cell lines. 
	   15	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Figure 5: Alignment of Human PDE3A and Human PDE3B.  Green bars represent 
conserved amino acids.  There is 41.224% conservation between both full-lenth proteins 
and 75.574% conservation between both catalytic domains (residues 670-1018 marked at 
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MATERIALS and METHODS 
 
Modeling of the intermolecular interactions between PDE3 and small molecules: 
Crystal structure of PDE3B (1SO2) was used to manually dock compounds Compound 
1B, TP5, Cilostazol, and Zadarvarine, designed in ChemBioDraw13.025 using PyMOL 
Molecular Graphics System26.   
 
Cell culture: Hela and MCF7 cell lines were maintained in Dulbecco’s Modification of 
Eagle’s Medium (Corning Cellgro) and A549, PC3, H1563, H2122 and COLO741 cell 
lines in Rosewell Park Memorial Institute (Corning Cellgro).  All media was 
supplemented with 10% FBS, and 1% penicillin and streptomycin and all cells were 
maintained at 37°C.  
 
Compounds: Compound 1B (R), Compound 1B (S), TP5, TP6, TP7, TP26, TP38, TP43, 
TP49, TP50 and TP51 were synthesized by Tim Lewis.  All other chemicals were 
purchased: Zardavarine (Sigma-Aldrich, Catalog #Z3003), Cilostazol (Sigma-Aldrich, 
Catalog #C0737), Levosimendan (Sigma-Aldrich, Catalog #L5545), Milrinone (Sigma-
Aldrich, Catalog #M4659), Sildenafil (Sigma-Aldrich, Catalog #PZ0003), Trequinsin 
(Sigma-Aldrich, Catalog #T2057), Siguazodan (Tocris Biosciences, Catalog #1148), and 
OR1896 (SantaCruz, Catalog #212689).  All compounds were dissolved in dimethyl 
sulfoxide (DMSO) and stored at –20°C.  
 
Cell viability assay in cell lines: A 40 µL cell suspension was added to wells of a 384-
well plate.  After 24 hours, cells were treated with 0.1 pM to 300 mM Compound 1B, 
analogs, or other selected PDE3A inhibitors.  48 hours after drug treatment, 10 µL of 
25% Cell Titer-Glo Luminescent Cell Viability Assay (Promega) and 75% phosphate-
buffered saline at room temperature was added and ATP fluorescence was read on the 
EnVison 2104 Multilabel Reader (PerkinElmer).  
 
PDE3A enzymatic activity assay in vitro General Protocol: The assay was developed 
based on PDE-Glo Phosphodiesterase Assay (Promega, Catalog #V1361).  Assay 
reagents were dissolved in Reaction Buffer (Promega).  1 µL of Reaction Buffer and 2.5 
µL of 5X Phosphodiesterase 3A (SignalChem, Catalog #P91-31G) enzyme was added to 
the reaction well of a 384 well plate.  2.5 µL of 5X cAMP was then added and incubated 
on the plate shaker for 20 minutes at room temperature.  As the reaction progressed, 
PDE3A hydrolyzed cAMP.  2.5 µL of Termination Buffer (containing a high 
concentration of IBMX) was added to the reaction well to completely inhibit the active 
PDE3A after 30 minutes immediately followed by 2.5 µL of Detection Solution 
containing inactive PKA and ATP.  The remaining cAMP that was not hydrolyzed by the 
PDE3A activated PKA by binding to its regulatory subunits and releasing its catalytic 
subunits.  Active PKA then transferred a phosphate group from ATP to substrate, 
depleting the concentration of ATP. 10 µL of Kinase-Glo (Promega) was added to the 
reaction well and incubated on the plate shaker for 10 minutes at room temperature in the 
dark.  The Kinase-Glo reagent contains luciferase, which uses the remaining ATP and 
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converts luciferin to oxyluciferin and in the process generates light proportional to the 
amount of ATP remaining.  This reaction is a measurement of the progression of the PKA 
catalyzed reaction because it measures remaining reactant ATP. The luminescence was 
measured on the Spectramax luminometer with an integration time of 1 second/well.  
Luminescence values were normalized to the appropriate control wells.  Controls for each 
experiment: 1) Reaction buffer as a blank; 2) No PDE3A or inhibitor as a low 
luminescence signal; 3) No cAMP as a high luminescence signal; 4) DMSO.  
 
A range of concentrations of PDE3A and cAMP as well as incubation times were tested 
separately with otherwise identical reaction conditions to determine the experimental 
conditions resulting in the greatest dynamic range of signal.  Schematic representation of 
the assay and representative luminescence output depicted in Figure 6 below. 
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Figure 6: Schematic of PDE3A Enzymatic Activity Assay.  A) The reaction and 
detection of the activity of PDE3A. B) Representative luminescence signal from control 
conditions for assay.  As cAMP concentration increased in the reaction well, the 
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Inhibitor assays:  Assays were performed using the General Protocol with 1 µL of 5X 
Compound 1B (racemic mixture and S- & R-enantiomer), known PDE inhibitors 
(Zardavarine, Cilostazol, Trequinsin), and analogs of Compound 1B (TP5, TP6, TP7, 
TP26, TP38, TP43, TP49, TP50 and TP51) dissolved in DMSO. The inhibitors were 
added to reaction wells containing Reaction Buffer and PDE3A at a final concentration of 
0.1% for a 10-minute incubation on a plate shaker, before proceeding to the rest of the 
assay described in the General Protocol.  The accumulated pool of cAMP, due to the 
inhibition of PDE3A hydrolysis of cAMP to 5’-AMP in the well, lowers the luminesence 
signal that is recorded on the Spectramax Luminometer.  Luminesence values for each 
concentration were divided by the DMSO control luminesence average, and were plotted 
as percentages at each concentration of inhibitor using GraphPad PRISM software.  The 
half-maximal concentration to inhibit the cAMP hydrolysis activity of PDE3A, or the 
IC50 values, were calculated with GraphPad PRISM software to compare the potencies of 
inhibitors.     
 
Kinetics Experiments: Assays were performed using the General Protocol with slight 
modifications.  First, Reaction Buffer, PDE3A (285 pg/µL), and the inhibitor were 
incubated for ten minutes, and then cAMP (0.3 µM) was added to start the reaction.  
After precisely two minutes, termination buffer was added to arrest the reaction.  The 
General Protocol was followed for the completion of the assay.  Inhibitor concentrations 
were chosen in a narrow range close to the IC50 value as determined by the in vitro 
Inhibitor Assay.  Luminescence was plotted against cAMP concentration for each 
concentration of inhibitor using GraphPad PRISM software.  
 
Luminescence output data was converted to velocity, for Michaelis-Menten visualization.  
This conversion was based on the following calculations.  Luminescence units were 
converted to velocity of the reaction by first calculating the amount of 5’-AMP product 
generated at each concentration of cAMP added and next dividing the product by the time 
of the reaction for velocity.  Example calculations for Zardavarine were used for the 
following transformation of assay output to a Michaelis-Menten visualization.  Cilostazol 
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Figure 7: The Normalized cAMP Standard Curve.  A. Luminescence values at each 
concentration of cAMP were converted from arbitrary units to a scale from 0 to 1. B. The 
data was transformed to log[cAMP] and a sigmoidal fit was assigned using PRISM 
software. 
 
The standard curve of the luminescence value at each concentration of cAMP was 
normalized so luminescence was measured as a function from 0 to 1, where Lx 
represented each data point collected, L0 represented the lowest luminescence signal at 
[cAMP] = 1 µM, and Lmax represented the highest luminescence signal where [cAMP] = 
0 µM.  This cAMP standard curve was created following the General Protocol, with the 
exception of adding Reaction Buffer instead of 1.5 µL of PDE3A in Reaction Buffer.  
Each point represented the luminescence signal that corresponded to each cAMP.  The 
[cAMP] values were transformed to log([cAMP]).  This transformation was applied in 
order to expand the visualization of the data points at very low concentrations of cAMP.  
The sigmoidal curve (Sigmoidal, X is log concentration) was applied using PRISM 
software based on the trend of the data (Figure 7).    
   𝐿! − 𝐿!"#𝐿!"# − 𝐿!"# = 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑  𝐿𝑢𝑚𝑖𝑛𝑒𝑠𝑐𝑒𝑛𝑐𝑒 
 𝑎𝑡   𝑐𝐴𝑀𝑃 = 0  µμM                 146,330− 52,280146,330− 52,280 = 1    𝑎𝑡   𝑐𝐴𝑀𝑃 = 1  µμM               52,280− 52,280146,330− 52,280 = 0  
 
Next, the average of the four replicate values of luminescence at each concentration of 
Zardavarine was calculated.  Averages were chosen instead of individual replicates to 
facilitate the interpolation.  These average values were normalized in the same manner 
where the maximum luminescence in the assay was 300,153 units at [cAMP] = 0 µM, 
[Zardavarine] = 0 µM and the minimum luminescence was 440 units at [cAMP] = 1 µM, 






































	   22	  
𝑎𝑡   𝑐𝐴𝑀𝑃 = 0  µμM                   300,153− 440300,153− 440 = 1    𝑎𝑡   𝑐𝐴𝑀𝑃 = 1  µμM               440− 440300,153− 440 = 0  
 
These luminescence values for Zardavarine were translated to their corresponding 
[cAMP].  The values of normalized luminescence were inputted to the normalized cAMP 
standard curve and values of corresponding [cAMP] were taken as output.  These output 
values represent the [cAMP]f once the reaction was terminated after two minutes.  
Extremely high values of normalized luminescence approaching a value of 1 could not be 
interpolated because the concentration of cAMP approached 0 and these data points were 
therefore excluded.  The [cAMP]i was the concentration added to the reaction well at the 
start of the reaction.  Therefore, the difference between these two values gave the 
concentration of the 5’-AMP product formed.  
 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 = 𝑐𝐴𝑀𝑃 ! − 𝑐𝐴𝑀𝑃 ! 
 
The [product] was divided by a 2 minute reaction time, yielding velocity (5’-AMP 
µM/min).   
 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 = 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑡𝑖𝑚𝑒  
 
The 2 minute reaction time was chosen because at all concentrations of cAMP, there was 
still cAMP remaining (Figure 8A), in other words, not all 5’-AMP was formed from the 
inputted cAMP (Figure 8B).  This indicated that there was plenty of available substrate 
for the PDE3A hydrolysis reaction.  At the 4 minute timepoint, there was only remaining 
cAMP substrate at 2 µM cAMP, and at the 30 minute timepoint, all [cAMP] was entirely 
consumed by the reaction.  Because reactions at 2 minutes still had substrate present, this 
timepoint was chosen for the subsequent kinetics studies.  Any shorter reaction time was 
not manually feasible within the limitations of the assay.   
 
Kinetic trends were observed using this visualization comparing known competitive 
inhibitors Zardavarine and Cilostazol to Compound 1B.  Data was visualized as 
Michaelis-Menten plots where reaction velocity was plotted against initial substrate 
concentration.  A two-step reaction was assumed: cAMP binds to PDE3A and then the 
cAMP substrate is hydrolyzed to 5’-AMP and released as product.  One assumption of 
Michaelis-Menten was that after reactions were terminated, there were still saturating 
substrate concentrations.  As seen in Figure 8, at each substrate concentration, there was 
remaining cAMP substrate.  Every PDE3A molecule therefore had substrate bound.  This 
PDE3A/cAMP complex was in steady state where the concentration was constant 
throughout the reaction.  We made assumptions that the binding step of cAMP to PDE3A 
was fast and the system quickly reached equilibrium, while the catalytic step was rate-
limiting.        
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Figure 8: Remaining [cAMP] After 2, 4, and 30 Minute Reaction Times.  A range of 
concentrations of cAMP from 0.0 µM to 2.0 µM initiated the reaction with 0.2 µM of 
PDE3A.  Reactions were terminated at 2, 4, and 30 minute time points.  A. The 
remaining [cAMP] at each initial [cAMP] was plotted. B. Alternative visualization where 
[5’-AMP] was plotted at each initial [cAMP].  The dotted line at y=x represented the 
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In this study we carried out a comparative analysis of the interaction between 
PDE3A & Compound 1B and known PDE inhibitors (Cilostazol and Zardavarine) in 
order to gain a structural and mechanistic understanding of how Compound 1B interacts 
with PDE3A.   This analysis was applied to cancer cell lines in order to make conclusions 
about the functional effect of the interaction between Compound 1B and PDE3A on the 
cAMP hydrolysis activity of PDE3A and about the selective toxicity of Compound 1B in 
cancer cell lines.  
 
Visualization of Compound 1B Bound to the Catalytic Site of PDE3B 
 
In the absence of a crystal structure for PDE3A, the use of the existing PDE3B 
structure (1SO2) for this study is justified due to the high sequence homology between 
PDE3A and PDE3B in the catalytic domain (Figure 5).  In order to visualize the 
molecular interactions of Compound 1B and PDE3B, a two-pronged approach was taken: 
first, the structural commonalities between cAMP, Zardavarine, Cilostazol, Compound 
1B and analog TP5 were analyzed; and second, conserved intermolecular interactions 
between models and co-crystal structures of cAMP/PDE3A27, Cilostazol/PDE3A27, and 
Zardavarine/PDE4D (PDB: 1XOR) were used as a guide to manually dock Compound 
1B in the crystal structure of PDE3B.  Structural and chemical similarities between 
cAMP, Zardavarine, Cilostazol, Compound 1B, and TP5 were analyzed in order to align 
the compounds and better understand the potential for interactions in the catalytic site of 
PDE (Figure 9).  Zardavarine, Cilostazol, Compound 1B, and TP5 share pyridazinone 
and benzene rings.  The partially negative charge of the carbonyl oxygen on the 
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pyridazinone ring is chemically similar to the negatively charged phosphate group of 
cAMP.  The presence of hydrogen bond donors and acceptors allows for specificity and 
strong interactions in the binding site; the oxygen and nitrogen of the pyridazinone ring 
acts as potential hydrogen bond acceptors, and the nitrogen of the (NH) acts as a potential 
hydrogen bond donor.  The adenine base of cAMP has the potential to take part in several 
hydrogen bonds, similar to the variable substituents of the benzene ring of the inhibitors.  
The benzene ring of the inhibitors acts as a spacer between the pyridazinone ring and the 
substituents of the benzene ring to mimic the furan ring of the ribose sugar in cAMP that 
bridges the phosphate to adenine.  The spacer could orient the substituents and the 
pyridazinone ring to facilitate their specific interactions.  These parallels between the 
inhibitors and cAMP provide chemical reasoning that all small molecules are equipped to 
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Figure 9: Chemical and Structural Similarities of Compound 1B, Analog TP5, PDE 
Inhibitors Zardavarine and Cilostazol, and Natural Substrate cAMP. Portions of the 
molecules were colored for comparison.  The adenine of the cAMP molecule and the 
substituents of the benzene rings of Compound 1B, TP5, Zardavarine and Cilostazol were 
colored red.  The furan ring of cAMP and the benzene rings of the other compounds were 
colored green.  The negatively charged phosphate group and the partially negative 
carboxylic oxygen were colored blue.  The pyridazinone rings of Compound 1B, TP5 and 
Zardavarine were highlighted in pink, as was the similarly structured ring of Cilostazol.  
 
Previously modeled compound/PDE complexes were analyzed in order to guide 
manual docking of Zardavarine, Cilostazol, Compound 1B, and TP5 in the structure of 
PDE3B.   Figure 10 highlights the key interactions between a model of cAMP and 
Cilostazol bound to PDE3A and a co-crystal structure of Zardavarine bound to PDE4D.  
Substrate binding includes an electrostatic interaction between the phosphate group of 
cAMP and the coordinated Zn2+, and a hydrogen bond with His752 (Figure 10A).  The 
furan ring of the ribose interacts with Tyr751, Leu910, and Ile968 through van der Waals 
forces.  The adenine base is hydrophobic, and is positioned near hydrophobic amino acids 
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Figure 10:  Model of cAMP and Cilostazol in Catalytic Site of PDE3A28 and 
Zardavarine in Catalytic Site of PDE4D.  Previous models and co-crystal structures 
were used to identify conserved interactions.  A. Key interactions between cAMP and 
Cilostazol compounds and PDE3A were conserved in our structural study.  The blue 
ribbon highlighted the secondary structure of the binding pocket while the orange sticks 
highlighted amino acids in the binding site.  The Zn2+ was represented as a blue hexagon.  
cAMP was marked in green and Cilostazol was marked in purple. B. Zardavarine 
crystallized in the catalytic site of PDE4D (PDB: 1XOR).  PDE3B was visualized using 
cartoon representation of the amino acid backbone.  The oxygen atoms were colored red 
and the nitrogen atoms were colored blue.  The carbon backbone was colored pink.  
Conserved residues important for binding, Ile 336, Gln 369 and Phe 372, and the 
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When analyzing the interactions between inhibitors (Zardavarine and Cilostazol) 
and the PDE catalytic domain, it became apparent that features of the catalytic site 
important for binding cAMP were also critical for interactions with the inhibitors due to 
their structural similarities.  The compounds were inserted into PDE3B by maintaining 
key interactions in the models between compounds and residues conserved across PDEs.  
Because Zardavarine and Cilostazol are bound in the active site of the PDEs when 
modeled, Compound 1B and analog TP5 were built into the same binding site of PDE3B 
(Figure 11).  These conserved interactions are described in the context of Compound 1B, 
but were based on the conserved interactions between residues of the catalytic domain of 
PDE and compounds Zardavarine, Cilostazol, and cAMP.    
A conserved isoleucine and phenylalanine create a hydrophobic clamp, which 
sandwiches and favorably interacts with the planar benzene ring of Compound 1B 
(Figure 11A).  This hydrophobic interaction is not specific, but is entropically favorable 
for the system overall, as it minimizes direct contact with water.  The amine functional 
group of glutamine has the potential to make specific hydrogen bonds with the 
substituents off of the benzene ring, specifically the nitrogen of the diethylamine of 
Compound 1B.  The polar nitro substituent on Compound 1B remains solvent exposed, 
oriented in the opposite direction of the hydrophobic protein core.  The negatively 
charged oxygen of the pyridazinone ring is electrostatically attracted to the Mg2+ bound 
in the active site.  Because Compound 1B, TP5, Zardavarine and Cilostazol share these 
chemical and structural features important for maintaining interactions with the 
conserved residues in the PDE active site, we hypothesized that the compounds bound in 
a similar fashion (Figure 11C).   
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As seen with Zardavarine and Cilostazol, when Compound 1B and TP5 are bound 
to the active site of PDE3, cAMP cannot bind to the active site at the same time.  This 
comparative visualization of these complexes along with chemical reasoning implied a 
competitive binding mechanism of Compound 1B. 
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Figure 11: Models of Compound 1B, Analog TP5 and Inhibitors Zardavarine and 
Cilostazol Interacting with Conserved Residues in the Catalytic Domain of PDE3.  
The crystal structure for PDE3B (1SO2) was used to create these models. PDE3B was 
visualized using an overlay of the surface representation with cartoon representation of 
the amino acid backbone beneath.  The oxygen atoms were colored red and the nitrogen 
atoms were colored blue.  The carbon backbone was colored pink.  Conserved residues 
important for binding, Ile 955, Gln 988 and Phe 991, and the magnesium cations were 
highlighted in blue. A. Compound 1B modeled in the binding pocket of PDE3.  B. 
Zoomed in portion of the catalytic domain with Compound 1B.  C. Comparison between 
the binding of Compound 1B to Zardavarine, Cilostazol and TP5.  
 
Optimization of PDE3A Activity Assay for in vitro Analysis of the Interaction 
Between PDE3A and Compound 1B  
 
In order to investigate the interaction between Compound 1B and PDE3A 
empirically, a PDE3A activity assay was developed to measure the cAMP hydrolysis 
activity of PDE3A alone and in the presence of a panel of compounds.  The catalytic 
domain, of PDE3A (amino acids 641-1009) was used for the developed assay that was 
based on PDE-Glo Phosphodiesterase Assay by Promega.  While buffers, reagents, and 
protocols were provided with the assay, the concentrations of PDE3A and  cAMP used in 
the assay, and the duration of the reaction needed to be optimized (Figure 12).  
 
Figure 12: Optimization of the PDE3A Activity Assay.  A. Optimization of reaction 
time and concentration of PDE3A. B. Optimization of concentration of cAMP.  C. 
Dynamic range of the optimized assay.  At high (1 µM) and low (1 nM) concentrations of 
Compound 1B ((S) and (R) enantiomers), Trequinsin, and Sildenafil, the luminesence 
was recorded.  Controls of Reaction Buffer, PDE3A & DMSO, cAMP & DMSO, and 
cAMP, PDE3A & DMSO were included.  Reaction time of 30 minutes, and 
concentrations of 285 pg/µL PDE3A and 0.3 µM cAMP were selected to ensure that 
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A range of concentrations of PDE3A and cAMP as well as incubation times were 
tested separately with otherwise identical reaction conditions to determine the 
experimental conditions resulting in the greatest dynamic range of signal.  The EC50 of 
PDE3A determined to be 285 pg/µL was set as the optimum PDE3A concentration for 
further experiments. This value was in the steep linear section of the curve ensuring high 
sensitivity in the assay, since slight inhibition of the enzyme would show a large decrease 
in luminesence (Figure 12A).  The recorded luminescence reached a maximum at 30 
minutes and stayed consistent for up to 2 hours at room temperature (Figure 12A); 
therefore a reaction time of 30 minutes was chosen for subsequent experiments.  The 
optimal cAMP concentration was determined to be 0.3 µM based on luminescence 
readings after serial dilutions of cAMP was incubated with 285 pg/µL of PDE3A (Figure 
12B).  This concentration was in the dynamic range of the assay and any higher 
concentration reached a plateau of zero luminesence ensuring that  any decrease in the 
concentration of cAMP by PDE3A hydrolysis would result in a drastic increase in 
luminesence from that of the 0.3 µM cAMP concentration.   
Once the reaction time, PDE concentration, and cAMP concentration were 
optimized, the dynamic range of the luminescence signal produced by the assay was 
tested for Control conditions as well as  several inhibitors at both high (1 µM) and low (1 
pM) concentrations (Figure 12C).  When the DMSO & cAMP only control condition was 
compared to the DMSO, cAMP & PDE3A experimental condition, a drastic increase in 
luminescence signal was observed, indicating the hydrolysis of cAMP by PDE3A.  Low 
doses of compounds did not alter the luminesence of the reaction, indicating a fully active 
PDE3A, comparable to the control condition without inhibitor.  High doses of 
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Compound1B (R), Trequinsin and Sildenafil all reduced the activity of the protein.  The 
(R) and the (S) enantiomers of Compound 1B, rather than the racemic mixture, were 
tested separately in this assay in order to determine if this stereochemistry was important 
in PDE3A binding.  When PDE3A was incubated with Compound 1B (S) at a high dose, 
its activity remained high indicating that Compound 1B (S) was incapable of inhibiting 
PDE3A.  These results suggested that Compound 1B (R), like known PDE3A inhibitors, 
inhibited the cAMP hydrolysis function of PDE3A. 
 In addition to determining whether compounds inhibited PDE3A or not, we were 
curious as to the relative potencies of Compound 1B, analogs, and known PDE3A 
inhibitors.  We therefore performed an activity assay with a range of inhibitor 
concentrations.  As the concentration of Compound 1B (R) was increased from 0.2 µM to 
3 µM, the cAMP hydrolysis activity of PDE3A was reduced from close to 100% to close 
to 0% (Figure 13).  The IC50 value was determined to be 1.480 µM.  As expected, 
Compound 1B (S) did not reduce the activity of PDE3A across these extended 
concentrations.  This result that PDE3A activity was inhibited by Compound 1B (R) in a 
dose-dependent manner confirmed previous results of inhibition at a high, but not a low 
dose.    
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Figure 13: The Effect of Compound 1B (R) and (S) on the cAMP Hydrolysis 
Function of PDE3A.  0.2 µM to 3 µM of Compound 1B (R) and (S) were incubated with 
PDE3A for 10 minutes before initiating the hydrolysis reaction with the addition of 
cAMP, following the General Protocol.  The % Activity of PDE3A was determined by 
dividing the luminescence output at each concentration by the highest luminescence 
signal at 0 µM of compound.  Error bars represented the standard deviation of four 
replicates. 
 
In order to determine how the potency of Compound 1B and structural analogs 
compare to PDE3 inhibitors, IC50 values were reported for analogs of Compound 1B and 
known PDE3 inhibitors (Figure 14).  Some structural analogs of Compound 1B, such as 
TP51, inhibited the cAMP hydrolysis activity of PDE3A at a higher potency than 
Compound 1B, with an IC50 value of 0.256 µM.  Other analogs, such as TP7 did not 
inhibit the cAMP hydrolysis activity of PDE3A at any concentration tested.  Trequinsin, 
a known PDE3 inhibitor, inhibited the activity of PDE3A at lower concentrations than 
Compound 1B, with an estimated IC50 value of 0.007 µM.  Other known PDE3 inhibitors, 
Zardavarine and Cilostazol had IC50 values of 20 µM and 130 µM respectively.  IC50 
values determined from this assay were compared to IC50 values in the literature (Figure 
14D).  The literature reported IC50 values for Zardavarine and Cilostazol are 
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approximately a thousand fold smaller than found using our enzymatic activity assay, 
whereas Trequinsin was a hundred times smaller than we report.  This discrepancy is 
likely due to different assay conditions, especially variable PDE3A concentration.  As 
seen in Figure 14D, Compound 1B was a potent inhibitor of the cAMP hydrolysis 
activity of PDE3A with a 1.48 µM IC50 , ranking fifth among the fourteen tested analogs 
and known inhibitors.  
 
Figure 14: The Effect of Compound 1B, Analogs, and Known Inhibitors on the 
cAMP Hydrolysis Function of PDE3A.  Indicated concentrations of compounds were 
incubated with PDE3A for 10 minutes before initiating the hydrolysis reaction with the 
addition of cAMP, following the General Protocol.  A. Trequinsin and analogs of 
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Compound 1B including TP5, TP6, TP7, TP26, TP38, TP43, TP49, TP50 and TP51.  B. 
Cilostazol.  C. Zardavarine.  The % Activity of PDE3A was determined by dividing the 
luminescence output at each concentration by the highest luminescence signal at 0 µM of 
compound. A “log (inhibitor) v. response – Variable slope (four parameter)” curve was 
fit to the data using PRISM software and this curve was used to determine the IC50 values 




Compound 1B Followed Kinetic Trends of Competitive Inhibitors of PDE3A 
 
In order to determine the effect of Compound 1B on the kinetics of the cAMP 
hydrolysis function of PDE3A, a comparative study of the kinetics with two known 
competitive inhibitors of PDE3A, Zardavarine and Cilostazol, was performed.  Both our 
modeling and binding studies suggested that Compound 1B binds at a very similar site to 
cAMP and competitive inhibitors of PDE3A.  Therefore, we tested whether kinetic trends 
of the hydrolysis reaction incubated with Compound 1B were also similar to those of the 
competitive inhibitors Zardavarine and Cilostazol.   Luminescence output of the kinetics 
assay was transformed to a Michaelis-Menten visualization to plot our kinetics data 
where the velocity of the reaction was plotted against substrate concentration.  Adhering 
to the assumptions of the Michaelis-Menten model, we expected to determine kinetic 
parameters Vmax and Km, where Vmax is the maximum velocity of the PDE3A hydrolysis 
reaction with infinite cAMP, and Km is value the concentration of cAMP substrate 
required for hydrolysis to occur at half the maximal rate.  Therefore a high Km value 
implies a higher concentration of substrate is necessary to achieve the half maximal rate 
and a weak binding of substrate to protein.  The presence of a competitive inhibitor 
effectively lowers the affinity of PDE3A for the cAMP; increasing concentrations of 
inhibitor increase the Km.  On the other hand, because infinite substrate will overcome the 
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effect of the competitive inhibitor, the maximum velocity that the enzyme can hydrolyze 
cAMP will not change with inhibitor present.         
At the time of experimentation, the unreacted input cAMP confounded the change 
in signal of reacted cAMP hydrolyzed into 5’-AMP product.  When the kinetics data was 
visualized as velocity versus initial substrate concentration, it was apparent that the Vmax 
plateau was not reached (Figure 15A). Although the kinetic parameters of Vmax and Km 
could not be determined, trends of the two competitive inhibitors were still apparent 
(Figure 15).  These quantitative trends are summarized in Table 1.  Because inhibitor 
concentrations for the kinetics experiments were chosen in close proximity of the IC50 
values, ratios of [Inhibitor] to their IC50 values were calculated for facilitated comparison.  
At low concentrations of cAMP, as inhibitor concentration increased, the velocity of the 
reaction decreased (Figure 15B and C).  At initial [cAMP] = 0.5 µM, as the concentration 
of Zardavarine was increased from 0.337 of its IC50 value to 0.867 of its IC50 value, the 
velocity decreased from 0.076 µM 5’-AMP formed/min to 0.051 µM/min (Table 1).  
Similarly, as the concentration of Cilostazol rose from 0.307 of its IC50 value to 0.922 of 
its IC50 value, the velocity decreased from 0.055 µM 5’-AMP formed/min to 0.053 
µM/min (Table 1).  In the uninhibited reactions, where concentrations of Zardavarine and 
Cilostazol were 0 µM, the velocity of the reaction was higher than any inhibitor 
concentration at 0.239 µM/min and 0.238 µM/min respectively (Table 1).  At low 
substrate concentrations, the reaction rate was decreased because the inhibitor effectively 
replaced the substrate at the binding site and hindered hydrolysis.  At higher initial 
concentrations of cAMP, such as 2 µM, the substrate was in excess compared to the 
inhibitor, and the reaction was essentially uninhibited.  At any concentration of 
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Zardavarine and Cilostazol, a velocity at 0.8 µM/min was reached (Table 1).  Even 
though all inhibitor concentrations converged at this velocity at 2 µM cAMP, a Vmax 
could not be determined without the presence of a plateau at this point (Figure 15A, B 
and C).  These previously reported competitive inhibitors, Zardavarine and Cilostazol, 
exhibited the trends of competitive inhibitors in this PDE3A enzymatic activity assay.  
The same analysis was repeated for Compound 1B, and we found that Compound 
1B followed the kinetic trends observed for competitive inhibitors, Zardavarine and 
Cilostazol (Figure 15D and Table 1).  At 0.5 µM cAMP, as the concentration of 
Compound 1B increased, the velocity of the reaction decreased.  As the concentration of 
Compound 1B rose from 0.203 of its IC50 value to 0.676 of its IC50 value, the velocity 
decreased from 0.103 µM 5’-AMP formed/min to 0.052 µM/min (Table 1).  Additionally, 
at 2 µM cAMP, any concentration of Compound 1B reached a velocity at 0.8 µM/min 
(Table 1).  Because the kinetic trends of a competitive inhibitor match those of 
Compound 1B, we concluded that Compound 1B behaved similarly when interacting 
with PDE3A.   
	   39	  
 
Figure 15: Visualization of Kinetics Data as Michaelis-Menten Plots for Competitive 
Inhibitors Zardavarine and Cilostazol, as well as Compound 1B.   A range of 
concentrations of Zardavarine, Cilostazol, and Compound 1B were incubated with 
PDE3A for 10 minutes before initiating the hydrolysis reaction with the addition of 
cAMP, following the General Protocol.  Reactions were incubated for 2 minutes before 
terminated with Termination Buffer.  Luminescence was measured as output for each 
reaction as seen for Zardavarine in A.  On the x-axis, [cAMP] represented initial substrate 
added to the reaction.  The luminescence values along the y-axis were a measure of total 
[cAMP] remaining after the termination of the reaction, obscuring the change in [cAMP] 
over the course of the reaction. Error bars represent standard deviation of four replicates.  
B, C and D.  In order to visualize Michaelis-Menten plots as velocity of 5’-AMP 
produced during the reaction versus initial substrate concentration, luminescence output 
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was transformed into a readout of product by subtracting the luminescence of cAMP 
without enzyme present from the luminescence of cAMP remaining after the reaction 
incubated with Zardavarine, Cilostazol and Compound 1B.  This difference in 
luminescence signal was converted to velocity.  The x-axis represented initial [cAMP] 
added to the reaction.  For the transformation, averages of luminescence were taken 
instead of all replicates, hence there are no error bars.  Several values of luminescence 
could not be converted to concentrations of 5’-AMP because these luminescence were so 
close to 1, thus concentrations of cAMP approached 0.      
    
Table 1: Quantification of the Reaction Velocity at Various Inhibitor and cAMP 
Concentrations. 
 
Compound IC50 µM 
[Inhibitor] 
µM [Inhibitor]/ IC50 
Velocity at 0.5 µM 
cAMP (µM/min) 
 
Velocity at 2.0 µM 
cAMP (µM/min) 
 
Zardavarine 20.76 0 0.000         0.239 0.800 
  7 0.337 0.076 0.801 
  10 0.482 0.054 0.800 
  13 0.626 0.051 0.799 
  18 0.867 0.051 0.800 
Cilostazol 130.20 0 0.000 0.238 0.802 
  40 0.307 0.055 0.801 
  80 0.614 0.050 0.800 
  100 0.768 0.050 0.801 
  120 0.922 0.053 0.801 
Compound 1B 1.48 0 0.000 N/A 0.823 
  0.1 0.068 N/A 0.803 
  0.3 0.203 0.103 0.800 
  0.6 0.405 0.100 0.801 
  1 0.676 0.052 0.801  
 
Rescue by Non-Lethal Compounds Indicated Competitive Inhibition in the Sensitive 
Hela Cell Line 
 
After determining that PDE3A was the single gene whose expression correlated 
with cellular sensitivity to Compound 1B, Compound 1B structurally and chemically 
“fit” in the binding site of PDE3A, and Compound 1B inhibited PDE3A in vitro 
following kinetic trends of known competitive inhibitors, we hypothesized that 
Compound 1B competitively inhibited PDE3A in cells.  In order to see evidence of 
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competitive inhibition in the sensitive Hela cell line, inhibitors that were not lethal to the 
Hela cell line, but that did inhibit PDE3A in vitro were co-treated with TP30, a potent 
analog of Compound 1B (Luc de Waal, Unpublished Data, 2013).  These non-lethal 
competitive inhibitors, Trequinsin, Milrinone, Cilostazol, Levosimendan, OR-1896 and 
Siguazodan, rescued the cell-death phenotype when co-treated with TP30 as seen by the 
right shift in the EC50 of the treatment with TP30 alone (Figure 16).  The non-lethal 
inhibitors essentially diluted the effect of the potent and lethal analog of Compound 1B.  
TP30 and by extension, Compound 1B, were competing for the same active site as the 
non-lethal competitive inhibitors.  This experiment connected our observation that 
Compound 1B was a competitive inhibitor of PDE3A in vitro with the observation that 
this competitive relationship held in the Hela cell line and was related to the cell lethality 
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Figure 16: Non-lethal PDE Inhibitors to Hela Cells Rescue the Lethal Effect of 
Compound 1B.  A. Cells were co-treated with Compound 1B and 10 µM of non-lethal 
Cilostazol, Levosimendan, OR1896, Siguazodan, or Milrinone.  After 48 hours of 
treatment, cell viability was assessed using the Cell Titer-Glo assay.  B. Structures of the 
non-lethal inhibitors (Luc de Waal, Unpublished Data, 2013).      
 
Comparison of the in vitro Potencies to the in vivo Lethality of Compound 1B, its 
Structural Analogs and Known PDE Inhibitors 
 
 In order to determine if the ability of Compound 1B to inhibit the cAMP 
hydrolysis activity of PDE3A was sufficient to explain its lethality in cancer cells, the in 
vitro potencies were compared to the ability of the compounds to induce selective cell 
death.  Compounds were divided into categories of combinations of in vitro (binder or 
non-binder) and cell lethality behavior (lethal or non-lethal): 1) lethal binders to PDE3A, 
2) non-lethal binders, and 3) non-lethal non-binders (Figure 17).  Lethal compounds 
TP26 and TP43 did not inhibit PDE3A in vitro at the concentrations tested.  We 
hypothesize that because these structures do not have all functional groups present in 
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relative concentrations of TP26 and TP43 were needed to cause Hela cell death, we 
assume that a higher concentration of these two compounds in vitro would inhibit 
PDE3A.  TP7, Compound 1B (S), and TP50 were non-lethal non-binders of PDE3A, 
indicating the limited flexibility of compounds to bind to the catalytic domain.  
Compounds lethal to the Hela cell line bound and inhibited PDE3A in vitro.  However, 
Trequinsin, a non-lethal binder, inhibited the cAMP hydrolysis function of PDE3A more 
potently than Compound 1B, a lethal binder.  This indicated that an optimal PDE3A 
inhibitor did not imply an optimal cytotoxic agent.  Compound 1B was modeled as bound 
to the catalytic site of PDE3A through comparison to known PDE3 inhibitors, structural 
analogs, and non-lethal PDE3 inhibitors.  In addition, Compound 1B was empirically 
validated as competing for this binding site in vitro and in the Hela cell line.  Because 
non-lethal PDE3 inhibitors rescued the lethal effect of Compound 1B, competitive 
binding was directly linked to the cytotoxic effect of Compound 1B. 
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Figure 17: Three Categories of Compounds Derived from Inhibitor Potencies in 
vitro (binders or non-binders) and Their Ability to Induce Selective Toxicity in 
Cancer Cell Lines (lethal or non-lethal).  Reported effective concentrations of 










































































































































































In this study we validated and characterized the effect of Compound 1B, a novel 
cytotoxic agent, on the enzymatic activity of its proposed molecular target, 
phosphodiesterase 3A (PDE3A).  Compound 1B shared chemical and structural 
similarities with other PDE inhibitors Zardavarine and Cilostazol.  The structural 
conservation of the PDE3A inhibitors was used to model Compound 1B and analog TP5 
into the binding site of the highly conserved PDE3B, in order to visualize the Compound 
1B/PDE3A complex and predict important interactions for binding.  These similarities 
proved to indicate mechanistic similarities as well.   When looking at the effect of 
Compound 1B on the kinetics of the cAMP hydrolysis of PDE3A, it was determined that 
Compound 1B, like Zardavarine and Cilostazol, competed with cAMP for the catalytic 
domain of PDE3A. 
An understanding of the empirical data and theoretical models of the effect of 
these compounds on PDE3A in vitro was juxtaposed with the lethality data in cell lines to 
infer the functional implications of this binding.  Known PDE3A inhibitors Trequinsin, 
Cilostazol were not lethal to cells, but were still extremely potent inhibitors of the 
enzymatic activity of PDE3A.  The existence of this non-lethal binder category of 
compounds implies that simply binding to PDE3A at the catalytic site is not sufficient to 
induce the lethality of Compound 1B in cells.  Additionally, because Compound 1B 
competitively inhibits cAMP hydrolysis activity of PDE3A as does lethal Zardavarine 
and non-lethal Cilostazol, competitively inhibiting the hydrolysis is also not sufficient for 
the selective toxicity of Compound 1B in cell lines.  The prediction that the binding of 
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Compound 1B to PDE3A in vitro was confirmed in the Hela cell line because non-lethal 
PDE3A competitive inhibitors rescued the lethal effect of Compound 1B.  Although 
Compound 1B induces its effect by binding to the catalytic site of PDE3A, its selective 
toxicity is likely due to some other mechanism derived from this complex aside from 
inhibiting the cAMP hydrolysis function of PDE3A.   
The structural investigation of Compound 1B bound to the catalytic domain of 
PDE3A prompted speculation as to how changes to Compound 1B would affect binding.  
Because space and favorable interactions in the active site are limited, structural analogs 
of Compound 1B, which deviate significantly from the conserved backbone, are not 
predicted to bind to PDE3.  The pyridazinone is conserved among compounds, and 
modifications (such as those present in TP7, TP50, and Compound 1B (S)) are therefore 
expected to prevent their binding (Figure 18, circled in white).  The amide nitrogen 
provides strong electron donation to the carbonyl oxygen; replacing the nitrogen with a 
carbon would no longer provide electron density to the carbonyl oxygen.  Atomic 
changes to the pyridazinone ring, such as replacing the NH proton with a methyl group, 
are expected to disrupt chemical integrity and interactions necessary for binding.  
Additionally, modifying atoms that have the ability to participate in hydrogen bonds 
would eliminate this binding potential.  For example, replacing the amide hydrogen with 
a methyl group would eliminate a specific hydrogen bond.  Replacing the nitrogen with a 
carbon would eliminate the hydrogen bond possibility as well.  The atoms of the 
pyridazinone are presumably important for binding, as changes are expected to decrease 
binding.  Replacing any nitrogen with oxygen would eliminate a hydrogen bond donor 
and add an acceptor.  Although variability in the substituents on the benzene ring was 
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tolerated for binding, larger modifications would presumably lead to steric hindrance in 
the binding site of PDE3 (Figure 18, circled in yellow).  Large substituents would not be 
able to exist in the same space as residues at the edge of the binding pocket, such as 
glutamine.  The chemical space that the compounds will be able to bind is limited by the 
chemical nature and size of the active site.  The importance of these chemical and 
structural modifications could be validated by mutating key residues in the binding site to 
see if elimination of an interaction also eliminates binding.  Additionally, these structural 
analogs could be synthesized if possible and tested to see which modifications eliminate 
binding to PDE3A.    
   
Figure 18: Proposed Key Features of PDE3 Inhibitors Important for Binding to the 
Catalytic Site.  The crystal structure for PDE3B (1SO2) was used to create this model. 
PDE3B was visualized using an overlay of the surface representation with cartoon 
representation of the amino acid backbone beneath.  The oxygen atoms were colored red 
and the nitrogen atoms were colored blue.  The carbon backbone was colored pink.  
Conserved residues important for binding, Ile 955, Gln 988 and Phe 991, and the 
magnesium cations were highlighted in blue.  The pyridazinone ring was circled in white 
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The empirical study of Compound 1B and other small molecules interacting with 
PDE3A in vitro revealed that Compound 1B follows similar kinetic trends as competitive 
inhibitors Zardavarine and Cilostazol (Figure 15).  Although the assay used in this study 
was well suited for observing the effect of inhibitors on the cAMP hydrolysis activity of 
PDE3A, there were several limitations of the assay, particularly that arose in the kinetic 
study.  First, the unreacted input cAMP obscured the change in signal of reacted cAMP 
hydrolyzed into 5’-AMP product because the assay could not distinguish the change in 
luminescence from before to after the reaction at each initial cAMP concentration.  Only 
later when the product was calculated and the data was visualized as velocity versus 
initial substrate concentration, was it apparent that Vmax plateau was not reached (Figure 
15).  The presence of this plateau is necessary to establish a maximum velocity and 
determine other kinetic parameters such as Km.  In future experiments, higher initial 
concentrations of cAMP would be inputted until a plateau was reached to allow for the 
comparison of how Compound 1B and other small molecules affect the kinetics of the 
cAMP hydrolysis reaction of PDE3A.     
Secondly, luminescence output relied on several reactions that translated the 
cAMP concentration left after the initial hydrolysis reaction.  These three subsequent 
reactions were assumed to proceed as follows: 1) the addition of a large amount of IBMX 
was assumed to terminate the hydrolysis reaction by obliterating the activity of PDE3A; 
2) all remaining cAMP was expected to activate PKA and the proportion of activated 
PKA was assumed to phosphorylate a substrate by converting ATP to ADP; and 3) the 
luciferase reaction was expected to catalyze a reaction where all remaining ATP was 
quantified as light.  Although these three reactions were in excess and assumed to convert 
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all the remaining cAMP into a luminescence signal, in reality, equilibria exists.  A more 
ideal assay would have fewer reactions between the quantification of the PDE3A 
hydrolysis reaction and the measure of output.  
A third limitation of the PDE3A activity assay was that it was an endpoint assay.  
This means that the assay was terminated at different time points by saturating the 
PDE3A with inhibitor IBMX, and only after the PDE3A was no longer active, the 
quantification of the progress of the reaction was measured.  Kinetic experiments are 
more commonly performed using real-time assays, where the reaction progress can be 
collected from one sample continuously over time.  The real-time assay eliminates 
unnecessary sample variation and monitors the reaction trajectory over time.  A real-time 
assay29 has been developed for the purpose of measuring the kinetic parameters of 
phosphodiesterases and could be used for future kinetic characterization of this system.  
Our purpose was to understand the mechanism of inhibition, and although trends were 
comparable between Compound 1B and competitive inhibitors, confirmation of 
competitive inhibition using kinetic parameters of a constant Vmax and increasing Km as 
inhibitor concentration increased, would be ideal using this real-time kinetic assay.  The 
real-time assay determines the initial rates of cAMP hydrolysis by purified PDE protein 
by coupling the product 5’-AMP to the oxidation of NADH using three enzymes, 
adenylate kinase, pyruvate kinase, and lactate dehydrogenase.  The spectrophotometric 
readout of product formation of the PDE hydrolysis reaction provides a continuous and 
therefore more accurate way to visualize the kinetic parameters of the reaction versus the 
readout of cAMP remaining from the PDE3A activity assay used in this study.   
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In our assays, the catalytic domain of PDE3A was used since the full-length 
PDE3A was not suitable for the activity assay due to significant instability after freeze-
thaw.  This shortened form of PDE3A protein may have masked informative results 
because previous studies suggest that the affinity of inhibitors for the catalytic site may 
depend on the presence of regulatory domains outside the catalytic domain of the PDE29.  
For example, it was found that a PDE4D inhibitor, Rolipram, was 50X more potent at 
inhibiting the full-length protein than the catalytic domain.  Other studies have suggested 
that cell lines expressing specific isoforms of PDE4D are more sensitive to inhibitors 
than other cell lines expressing another isoform30.  It has been proposed that regulatory 
domains finely control the activity of PDE4 by exposing or blocking cAMP from 
entering the catalytic site29.  These conformations are controlled by phosphorylation of 
the regulatory domains or the presence of partner proteins.  The structural changes of the 
protein could be important for PDE3 as well because of the homology between PDE3 and 
PDE4 and because of the structural similarity across PDE inhibitors.  Conformational 
changes in regulatory domains of PDE3A induced by inhibitors binding to the catalytic 
site could be responsible for selective toxicity in cell lines.  
These findings of differential inhibition emphasize the need for understanding the 
isoforms present in the sensitive and nonsensitive cell lines to Compound 1B before we 
can elucidate the mechanism of selective toxicity.  Applying these findings to our model, 
quantification of isoforms present in cell lines sensitive or nonsensitive to Compound 1B 
could reveal a correlation between specific isoform expression and sensitivity.   
Differential expression of isoforms with unique regulatory domains present could effect 
the regulation of the activity of the protein aside from the cAMP hydrolysis activity, such 
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as another interaction of PDE3A not yet characterized.  The presence or absence of 
isoforms with the NHR1 and NHR2 regulatory domains could affect the binding of 
Compound 1B, and the ability to induce cell death aside from the cAMP hydrolysis 
function of the protein.  The potency of Compound 1B in cell lines, in contrast to inactive 
analogs could be explained by the lack of favorable interactions directly between the 
compound and a regulatory domain or by the ability of the compound to induce an 
allosteric change elsewhere in PDE3A.  Further inhibitor studies with various isoforms of 
the protein can be tested to determine if this relationship is true.  These experiments 
would be performed in cell lines since cellular components necessary for phosphorylation 
or potential interactions with PDE3A would be relied on to perhaps see the functional 
effect (with lethality as output) of the binding of Compound 1B.  Furthermore, mutational 
studies with a regulatory region believed to enhance the binding of an inhibitor could be 
performed to validate these interactions.  Thermal denaturation assays could reveal 
further information of conformational differences between complexes of 
PDE3A/Compound 1B and PDE3A/non-lethal inhibitor.  The isoform composition of 
cancer cell lines in conjunction with further structural insight on the PDE3A/compound 
complexes formed will reveal if sensitivity and isoform are correlated, implying that a 
regulatory mechanism of PDE3A may be involved in this phenotype of selective toxicity.             
Similar findings to this study of the differential efficacy of PDE3 inhibitors have 
been reported involving megakaryocyte differentiation.  Megakaryocytes are large cells 
in the bone marrow responsible for the production of platelets.  A PDE3 inhibitor, 
Anagrelide, has been FDA approved to treat essential thrombocytosis, or high platelet 
count, by reducing megakaryocyte differentiation.  However, the mechanism by which 
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Anagrelide affects megakaryocytes is not well understood31.  Although Anagrelide is a 
potent inhibitor of the cAMP hydrolysis function of PDE3, this function is not believed to 
cause the inhibition of megakaryocyte differentiation.  Ahluwalia et al. reported that not 
all PDE3 inhibitors induced the differential inhibition of megakaryocyte differentiation; 
specifically, Anagrelide, but not an equipotent PDE3 inhibitor Cilostamide, suppressed 
megakaryocyte development by reducing the expression of transcription factors GATA-1 
and FOG-132.  Because of the differential effect of PDE3 inhibitors, the authors 
concluded that a mechanism other than PDE3 inhibition was causing their phenotype.  
Wang et al. concluded that Anagrelide inhibits megakaryocyte differentiation in a PDE3-
independent manner33.  Both studies prematurely concluded that this phenotype is PDE3-
independent.   Their conclusions would have been convincing if they knocked-down 
PDE3A and cells treated with Anagrelide still inhibited megakaryocyte differentiation, 
while those incubated with Cilostamide did not.  Otherwise, they cannot conclude solely 
on the discrimination of inhibitors that their phenotypic effect is PDE3-independent. 
Despite these premature conclusions, their findings of inhibitor discrimination 
align with the findings we report.  Although our lethality phenotype is observed in 
selected cancer cell lines, and inhibition of differentiation is observed in megakaryocytes, 
in both systems select PDE3 inhibitors induce the phenotypic effect while others do not.  
In our cancer cell line system, Angrelide induces the lethality phenotype (Hela EC50 = 
7.6-9.6 nM), while Cilostamide does not (Hela EC50 = >10,000 nM).  But unlike the 
previous studies on megakaryocyte differentiation, we are confident that our mechanism 
is PDE3-dependent because when PDE3A was knocked-out in sensitive cancer cell lines, 
Compound 1B no longer reduced viability (Luc de Waal, Unpublished Data, 2014).  It is 
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conceivable that these systems are similar in the sense that the Anagrelide or Compound 
1B/PDE3A complex is involved in a related pathway that induces these observed 
phenotypes.  We have shown that very similar small molecules to Compound 1B will 
also bind to the catalytic domain of PDE3A, but do not induce the interaction necessary 
to cause the observed phenotype of cell death.  This novel role of the inhibitor/PDE3A 
complex in a pathway related to lethality and perhaps megakaryocyte differentiation is 
outside the realm of inhibiting cAMP hydrolysis, and has not yet been determined in 
either system.  
Although Compound 1B inhibits cAMP hydrolysis, this function alone is not 
sufficient for the lethality phenotype.  The suggested novel role of PDE3A could be 
induced by a conformational change that occurs when Compound 1B is bound.  This 
conformational change could prevent or enhance the ability of PDE3A to be 
phosphorylated, differentially localized, or capable of binding to a novel partner – a 
change that induces cancer cell death.  One approach to uncover the implication of this 
complex is to perform an interaction assay in the presence of Compound 1B or a non-
lethal competitive inhibitor.  A Stable Isotope Labeling by Amino acids in Cell culture34 
(SILAC) assay will be performed to co-precipitate interacting proteins with PDE3A 
incubated with Compound 1B and compare those proteins to the interactome in the 
presence of a non-lethal inhibitor.  This quantitative proteomic approach incorporates 
heavy or light non-radioactive isotope-containing amino acids into newly synthesized 
proteins.  For example a sensitive cell line incubated with Compound 1B could have 
heavy isotopes incorporated into synthesized proteins, while the same cell line incubated 
with a non-lethal inhibitor could have light isotopes incorporated.  The isotopes allow for 
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the two protein populations to still be distinguishable after mixing the populations and 
co-precipitating with PDE3A at once to avoid variation in the handling of samples.  The 
proteins and their abundances are identified by mass spectrometry and the differences in 
the interactomes of PDE3A can therefore be identified.  These differences could reveal 
co-precipitating proteins from a novel biological interaction involving PDE3A, which is 
responsible for the cell lethality phenotype we observed.        
The results of this study embody a close analysis of the interaction of a small 
molecule probe, emerging from a screen, and its target.  Our study provides insight into 
the function of this probe, but the mechanism responsible for lethality has yet to be 
discovered.  We assert that competitive binding of Compound 1B to PDE3A is important 
to conferring the signal for cell death in sensitive cancer cells, but further investigation is 
necessary to reveal the mechanism of this phenomenon in order to determine if treatment 
with Compound 1B or another therapy is a feasible therapeutic approach.  As chemical 
screens are increasingly common to probe a biological question, functional follow-up is 
crucial to potentially translate experimental findings into therapeutics.  Although the 
probes themselves may not be applied clinically, scientists will use them to provide 
insight in the novel pathways related to the biological phenotype.  The current paradigm 
of drug development is often target driven, based on designing a compound to bind to a 
target, but far too often, the desired biological phenotype based on this interaction is 
difficult to achieve.  The approach of selecting a probe from a phenotypic screen presents 
the challenge of uncovering the mechanism of action of the compound, but ensures that 
the compound induces the desired biological phenotype – a characteristic crucial for 
therapeutic development. 
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